ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that the Company’s Board of Directors has appointed Russell Skibsted to the position of Chief Financial Officer, succeeding Robert Peabody.
Help employers find you! Check out all the jobs and post your resume.
